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PREVALENCE OF FIBROMYALGIA IN RUSSIA
Le Lay K1, Nasonov E2, Soldatov D3, Taieb C1
1Pierre Fabre, Boulogne, France, 2Rheumatology Institute, Moscou, Russia, 3Pierre Fabre 
Laboratories, Moscou, Russia
OBJECTIVES: To assess the estimated prevalence of ﬁ bromyalgia syndrome (FM)
among the adult population in the general population in Russia, using the London
Fibromyalgia Epidemiology Study – Screening Questionnaire (LFESSQ) and American
College of Rheumatology (ACR) classiﬁ cation criteria. METHODS: The validated 
Russian version of the LFESSQ was administered to a representative community sample 
of 1,610 subjects aged over 15 years, selected by the quota method. A positive screen 
was deﬁ ned as: (1) meeting the 4-pain criteria alone (LFESSQ-4), or meeting both the
4-pain and 2-fatigue criteria (LFESSQ-6). The questionnaire was submitted to a sample 
of rheumatology outpatients (n  399), who were then examined by a trained rheu-
matologist to conﬁ rm or exclude the diagnosis of FM according to the 1990 American 
College of Rheumatology criteria. The prevalence of FM in the general population
was estimated by applying the predictive positive value to eligible community subjects
(i.e., positive screens). RESULTS: In the community sample, 13.8% screened positive
for LFESSQ-6 (18.4% in females and 8.1% in males respectively). Among rheumatol-
ogy outpatients, 43.6% were screened positive (44.3% in females and 40.5% in males
respectively), whereas 6.5% were conﬁ rmed FM cases. The prevalence of FM was 
estimated at 2.1% (95% CI: 1.4%–2.8%, 2.8% in females and 1.2% in males respec-
tively) in the Russian general population. CONCLUSIONS: Our ﬁ ndings are in
agreement with those of earlier national survey reports. A point prevalence of 2.1%
would translate in approximately 2.5 million of patients with FM in Russia.
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30 DAYS MORTALITY FOLLOWING FEMORAL NECK FRACTURE IN THE
PRESENCE OF DIFFERENT CO-MORBIDITIES
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OBJECTIVES: The aim of our study is to analyze the relationship between surgical
delay over 24 hours and 30 days mortality following femoral neck fracture in the 
presence of different co-morbidities in patients aged over 60 years. METHODS: Data
were derived from the database of the National Health Insurance Fund Administration 
according to the ICD 10th revision’s S7200 code. The study included patients aged
over 60 years old discharged from inpatient care institutions following the primary 
treatment of femoral neck fractures. The patients with polytrauma were excluded from
the study. In case of surgical delay six hours mortality was the reference. Data were
evaluated according to sex, age, type of fracture, patient turnover of institutions, type
of surgery, early complications, hospital type, day of operation. The following co-
morbidities were included into the analysis: C00-C97, D60-D64, E10-E16, F00-F99, 
G20-G26, G80-G83, I10-I15, I20-I25, I30- I52, I60-I69, I70, J00-J22, J40-J47, L89, 
N30-N39). Statistical analysis has been performed by logistic regression (Odds
Ratio(95%CI), p  0,05). RESULTS: Altogether 3783 patients were involved into
the study. Surgical delay (24 h/0–6 h) OR  1.5009, p  0.0095. The following co-
morbidities (ICD codes with OR and p value) proved to be statistically signiﬁ cant 
predictors: C00-C97: 2,6381(0.0274), G80-G83: 2.5984(0.0224), I20-I25:
1.6125(0.0438), I30-I52: 2.2758(0.0246), I70: 1.7281(0.0328), J00-J22: 2.2884(0.04), 
J40-J47: 2.3204(0.0141). CONCLUSIONS: Longer than 24 hours surgical delay sig-
niﬁ cantly increased the risk of 30 days mortality compared to 6 hours delay. The
longer than 24 hours surgical delay of treatment of elderly femoral neck fracture
proved to be statistically signiﬁ cant predictors of 30 days mortality: malignancies,
cerebral paralyzed disorders, ischemic and other heart diseases, arteriosclerosis, infec-
tions of the upper and lower respiratory system and chronic diseases of the lower 
respiratory system. In order to decrease the risk of early mortality it is essential strive
after earliest surgical treatment with special respect the high risk patient group with 
co-morbidities.
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OBJECTIVES: The aim of our retrospective study is to analyze the relationship 
between type of operation and 30 days mortality following femoral neck fracture in
the presence of different co-morbidities in patients aged over 60 years. METHODS:
Data were derived from the database of the National Health Insurance Fund Admin-
istration according to the ICD 10th revision’s S7200 code. The study included patients
aged over 60 years old discharged from inpatient care institutions following the
primary treatment of femoral neck fractures. The patients with polytrauma were 
excluded from the study. Osteosynthesis was compared to arthroplasty as reference
surgical method. Data were evaluated according to sex, age, type of fracture, patient
turnover of institutions, surgical delay, early complications, hospital type, day of 
operation. The following co-morbidities were included into the analysis: C00-C97, 
D60-D64, E10-E16, F00-F99, G20-G26, G80-G83, I10-I15, I20-I25, I30- I52, I60-
I69, I70, J00-J22, J40-J47, L89, N30-N39). Statistical analysis has been performed 
by logistic regression (Odds Ratio[95%CI], p  0.05). RESULTS: Altogether 3783 
patients were involved into the study. Type of surgical intervention (osteosynthesis/
arthroplasty) OR: 1.7265, p: 0.0128. The following co-morbidities (ICD codes 
with OR and p value) proved to be statistically signiﬁ cant predictors: I10-I15:
2,0759(0.0136), I60-I69: 2.5104(0.0498), J40-J47: 2.8177(0.0305). CONCLU-
SIONS: Osteosynthesis signiﬁ cantly increased the risk of 30 days mortality compared
to arthroplasty. Osteosynthesis treatment of elderly femoral neck fracture proved to 
be statistically signiﬁ cant predictors of 30 days mortality: cerebrovascular disorders 
and chronic diseases of the lower respiratory system. A possible explanation of the 
difference in mortality can be that because of the higher risk of arthroplasty more
healthy patients are selected for arthroplasty, while patient with poorer general health
status undergo osteosynthesis having lower surgical risk.
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ESTIMATION OF LIFE EXPECTANCIES AND LOSS OF LIFE
EXPECTANCIES FOR WORKERS WITH PERMANENT OCCUPATIONAL
DISABILITY OF UPPER AND LOWER LIMBS: A FOLLOW-UP STUDY OF
69,964 WORKERS FOR 21 YEARS
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OBJECTIVES: This study intends to estimate the life expectancies and loss of life 
expectancies for workers with permanent occupational disability of upper and lower
limbs in Taiwan. METHODS: We collected all cases of permanent occupational dis-
ability from the database of compensation claim of Bureau of Labor Insurance between 
1986 and 2006, which were linked with the national mortality registry to obtain the 
survival function. We generated survival curve for age- and sex-matched reference 
population from the life table of the Taiwan general population in 2000 through Monte 
Carlo method. Lifetime survival of the workers (up to 1000 months) were obtained
using linear extrapolation of a logit-transformed curve of the survival ratio between 
the workers and reference populations. RESULTS: The life loss for workers with leg
amputation and injury were 51.5 o 19.7, and 98.0 o 16.8 life-months, respectively,
while those for workers with arm amputation and injury were 153.9 o 63.1 and 81.5 
o 29.3, respectively. However, workers with permanent toes and ﬁ ngers showed no 
statistically signiﬁ cant loss of life expectancies compared with the general populations.
CONCLUSIONS: Workers with permanent occupational disability of arm or leg suf-
fered from signiﬁ cant loss of life expectancies, which should be considered for com-
pensation and cost-effectiveness analysis of prevention for these populations.
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WITH GOUT TO THOSE WITH DIFFICULT TO MANAGE GOUT
Raisch DW1, Campbell HM2, Khan N3, Rice J2
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OBJECTIVES: To measure the health care utilization of US veteran patients with gout 
and to determine additional costs associated with difﬁ cult to manage gout (DMG).
METHODS: Using diagnostic codes (ICD-9 CD  274.XX), we identiﬁ ed patients 
with gout in 2004 from the national Veterans Affairs Health Care System (VA) data-
bases. We then collected all administrative data (demographic, inpatient and outpa-
tient care, pharmacy, laboratory, and tests) for these patients over the years 2004–2006.
DMG patients were identiﬁ ed by diagnostic codes associated with complications of 
the skin (tophi), eye, nerve, and kidney. We created data summaries for each patient 
by year; including diagnoses, treatments, drug therapies, laboratory tests, and surger-
ies. RESULTS: There were 200,772 patients identiﬁ ed in 2004. Each year, heathcare 
costs per patient were signiﬁ cantly higher (Kruskal Wallis tests, P  0.001) for DMG 
versus other gout patients: inpatient costs in 2006. In addition DMG patients were 
signiﬁ cantly (P  0.001), had higher Charlson co-morbidity scores and were more 
likely to have concomitant cardiovascular, renal, and liver diseases. A limitation of 
the study is the lack of speciﬁ city of diagnostic codes for complications due to gout, 
which may impact the sample size. CONCLUSIONS: Health care costs are signiﬁ -
cantly higher for DMG patients. We note that increased inpatient plus outpatient costs 
for DMG patients were $10,000 to $16,000 per patient-year. These VA patients also
have signiﬁ cantly more co-morbid conditions than other gout patients.
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ESTIMATION OF COSTS RELATED TO ADVERSE EVENTS IN NSAID
TREATMENT OF OSTEOARTHRITIS – A COMPARISON BETWEEN 
CELECOXIB AND IBUPROFEN USING A VALIDATED MODEL
Svedbom A1, Borgstrom F1, Holmstrom S2, Miltenburger C3
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OBJECTIVES: To quantify and compare the overall adverse event (AE) related costs 
and their constituents associated with celecoxib and traditional NSAID treatment in
osteoarthritis (OA). METHODS: Using an amended version of a recent NICE Markov
